IGC Share Price Performance
US$0.35
-0.05 (-12.95%)
Price US$0.35
Share PriceUS$0.35
IGC Community Narratives
There are no narratives available yet.
Recent IGC News & Updates
No updates
IGC Pharma, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.085
- Gross Margin
- 48.70%
- Net Profit Margin
- -560.27%
- Debt/Equity Ratio
- 2.1%
IGC Pharma, Inc. Competitors
About IGC
- Founded
- 2005
- Employees
- 70
- CEO
- WebsiteView website
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading